PubRank

Kazuo Umezawa

Author PubWeight™ 128.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007 1.59
2 TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J Biochem 2011 1.46
3 Introduction of human β-defensin-3 into cultured human keratinocytes and fibroblasts by infection of a recombinant adenovirus vector. Burns 2010 1.45
4 Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. Leuk Res 2006 1.40
5 Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 2007 1.28
6 BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006 1.25
7 Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002 1.21
8 Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2004 1.19
9 Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler Thromb Vasc Biol 2007 1.16
10 Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008 1.13
11 Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling. J Biol Chem 2003 1.11
12 A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005 1.09
13 Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008 1.09
14 Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005 1.09
15 Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005 1.08
16 Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 2003 1.08
17 Hydrogen and N-acetyl-L-cysteine rescue oxidative stress-induced angiogenesis in a mouse corneal alkali-burn model. Invest Ophthalmol Vis Sci 2011 1.06
18 ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A 2012 1.04
19 JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005 1.04
20 Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J Urol 2003 1.02
21 Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 2004 1.02
22 Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochem Biophys Res Commun 2010 0.99
23 In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005 0.98
24 Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J Med Chem 2003 0.97
25 A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. J Crohns Colitis 2011 0.97
26 Molecular mechanisms regulating dissociation of cell-cell junction of epithelial cells by oxidative stress. Genes Cells 2009 0.95
27 Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009 0.94
28 Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 2008 0.93
29 Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncol 2011 0.92
30 Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005 0.92
31 Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer 2009 0.91
32 A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb 2006 0.90
33 Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. Int J Oncol 2006 0.90
34 Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma. Invest Ophthalmol Vis Sci 2009 0.89
35 The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett 2012 0.89
36 Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid. Leuk Res 2002 0.89
37 A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett 2009 0.89
38 Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats. Biomed Pharmacother 2009 0.89
39 Donor pretreatment with DHMEQ improves islet transplantation. J Surg Res 2010 0.88
40 Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines. Urology 2010 0.87
41 Biological activities of alpha-mangostin derivatives against acidic sphingomyelinase. Bioorg Med Chem Lett 2003 0.87
42 Conophylline: a novel differentiation inducer for pancreatic beta cells. Int J Biochem Cell Biol 2005 0.87
43 Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. Biochemistry 2004 0.87
44 The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. J Surg Res 2008 0.87
45 The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-κB inhibitors in Hodgkin's lymphoma. Cancer Sci 2010 0.87
46 Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol 2009 0.86
47 The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008 0.86
48 Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma. Neuro Oncol 2011 0.86
49 Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci 2009 0.85
50 Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation 2006 0.85
51 Controlling methicillin-resistant Staphylococcus aureus by stepwise implementation of preventive strategies in a university hospital: impact of a link-nurse system on the basis of multidisciplinary approaches. Am J Infect Control 2007 0.85
52 Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. FEBS Lett 2012 0.85
53 Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells. Expert Rev Anticancer Ther 2003 0.84
54 Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 2005 0.84
55 Dopaminergic modulation on respiratory rhythm in rat brainstem-spinal cord preparation. Neurosci Res 2004 0.84
56 A simple method to induce differentiation of murine bone marrow mesenchymal cells to insulin-producing cells using conophylline and betacellulin-delta4. Endocr J 2008 0.84
57 Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Inflamm Res 2011 0.84
58 Nitric oxide donors induce neurotrophin-like survival signaling and protect neurons against apoptosis. Mol Pharmacol 2005 0.84
59 Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat 2007 0.84
60 Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology 2011 0.84
61 Determination of cathepsin V activity and intracellular trafficking by N-glycosylation. FEBS Lett 2012 0.84
62 Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ. Biochem Biophys Res Commun 2008 0.84
63 In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. Leuk Res 2005 0.84
64 Role of NF-κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. Lasers Surg Med 2011 0.83
65 Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol 2010 0.83
66 Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head Neck 2006 0.83
67 Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin Cancer Res 2009 0.83
68 Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha. Arthritis Res Ther 2012 0.83
69 Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci 2011 0.83
70 Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect 2008 0.83
71 Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB. Org Biomol Chem 2012 0.83
72 Determination of topological structure of ARL6ip1 in cells: identification of the essential binding region of ARL6ip1 for conophylline. FEBS Lett 2013 0.83
73 Migracins A and B, new inhibitors of cancer cell migration, produced by Streptomyces sp. J Antibiot (Tokyo) 2012 0.82
74 Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. Invest Ophthalmol Vis Sci 2009 0.82
75 Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. Bioorg Med Chem Lett 2011 0.82
76 Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. Clin Exp Metastasis 2012 0.82
77 Promotion of beta-cell differentiation by conophylline in fetal and neonatal rat pancreas. Diabetes 2004 0.82
78 DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol 2006 0.82
79 Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes. Diabetes 2013 0.82
80 Inhibition of lipopolysaccharide activity by a bacterial cyclic lipopeptide surfactin. J Antibiot (Tokyo) 2006 0.82
81 NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res Ther 2007 0.82
82 Synthesis and biological evaluation on novel analogs of 9-methylstreptimidone, an inhibitor of NF-kappaB. Bioorg Med Chem Lett 2009 0.82
83 Coffee induces breast cancer resistance protein expression in Caco-2 cells. Biol Pharm Bull 2011 0.81
84 Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ. Oncol Res 2013 0.81
85 Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anticancer Drugs 2012 0.81
86 Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. Mol Cancer Ther 2005 0.81
87 Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ. Microbes Infect 2010 0.81
88 Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem 2009 0.81
89 Isolation of a novel cyclic hexadepsipeptide pipalamycin from Streptomyces as an apoptosis-inducing agent. J Antibiot (Tokyo) 2002 0.81
90 Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. Transplantation 2013 0.81
91 Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma. Drug News Perspect 2006 0.81
92 The efficacy of rewarming with a portable and percutaneous cardiopulmonary bypass system in accidental deep hypothermia patients with hemodynamic instability. J Trauma 2008 0.81
93 DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. J Dermatol Sci 2008 0.80
94 Overexpression of phosphatidylinositol synthase enhances growth and G1 progression in NIH3T3 cells. Jpn J Cancer Res 2002 0.80
95 Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Hum Immunol 2010 0.80
96 Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. Biochem Biophys Res Commun 2009 0.80
97 Involvement of NF-κB-mediated expression of galectin-3-binding protein in TNF-α-induced breast cancer cell adhesion. Oncol Rep 2012 0.80
98 The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. Nephron Exp Nephrol 2008 0.80
99 Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines. Bioorg Chem 2003 0.80
100 Effect of a novel nuclear factor-κB activation inhibitor on renal ischemia-reperfusion injury. Transplantation 2013 0.80
101 p62/SQSTM1 plays a protective role in oxidative injury of steatotic liver in a mouse hepatectomy model. Antioxid Redox Signal 2014 0.80
102 Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin. Jpn J Clin Oncol 2007 0.80
103 Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. Bioorg Med Chem Lett 2005 0.79
104 Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. Cancer Lett 2007 0.79
105 Efficient cellular uptake of the novel NF-kappaB inhibitor (-)-DHMEQ and irreversible inhibition of NF-kappaB in neoplastic cells. Oncol Res 2010 0.79
106 Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow. Oncol Res 2005 0.79
107 Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. Transplantation 2013 0.79
108 Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor. Int J Oncol 2005 0.79
109 DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. Immunology 2008 0.79
110 A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett 2003 0.79
111 Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer Lett 2008 0.78
112 Conophylline and betacellulin-delta4: an effective combination of differentiation factors for pancreatic beta cells. Endocr J 2007 0.78
113 Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. Biomed Pharmacother 2008 0.78
114 Suppression of inflammatory cytokine secretion by an NF-ĸB inhibitor DHMEQ in nasal polyps fibroblasts. Cell Physiol Biochem 2012 0.78
115 Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. Ann N Y Acad Sci 2009 0.78
116 Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells. Oncol Res 2012 0.78
117 Screening of new bioactive metabolites for diabetes therapy. Intern Emerg Med 2013 0.78
118 Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. Org Biomol Chem 2011 0.78
119 Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB. Int J Oncol 2011 0.78
120 Preparation of conophylline affinity nano-beads and identification of a target protein. Bioorg Med Chem 2009 0.78
121 Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappaB inhibition. J Allergy Clin Immunol 2010 0.77
122 Is the combination therapy of IKr-channel blocker and left stellate ganglion block effective for intractable ventricular arrhythmia in a cardiopulmonary arrest patient? Cardiol J 2007 0.77
123 IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab Invest 2007 0.77
124 Conophylline suppresses hepatic stellate cells and attenuates thioacetamide-induced liver fibrosis in rats. Liver Int 2013 0.77
125 Screening of bioactive metabolites for pancreatic regeneration chemotherapy. Biomed Pharmacother 2004 0.77
126 Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts. Graefes Arch Clin Exp Ophthalmol 2014 0.77
127 A novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice. Am J Nephrol 2013 0.77
128 Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells. Oncol Res 2013 0.77
129 A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008 0.77
130 Adrenaline contributes to prenatal respiratory maturation in rat medulla-spinal cord preparation. Brain Res 2006 0.77
131 Administration of conophylline and betacellulin-delta4 increases the beta-cell mass in neonatal streptozotocin-treated rats. Endocr J 2009 0.77
132 Inhibition of lysenin-induced hemolysis by all-E-lutein derived from the plant Dalbergia latifolia. Planta Med 2012 0.77
133 Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells. Exp Cell Res 2007 0.77
134 Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. Leuk Res 2007 0.77
135 Effects of DHMEQ, a novel nuclear factor-kappab inhibitor, on beta cell dysfunction in INS-1 cells. Endocr J 2008 0.77
136 Dopamine desynchronizes the pace-making neuronal activity of rat respiratory rhythm generation. Eur J Neurosci 2006 0.77
137 Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes. Clin Exp Pharmacol Physiol 2010 0.77
138 Apoptosis in mouse amniotic epithelium is induced by activated macrophages through the TNF receptor type 1/TNF pathway. Biol Reprod 2010 0.76
139 Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome. Mod Rheumatol 2013 0.76
140 A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ. Bioorg Med Chem Lett 2010 0.76
141 Dehydroxymethylepoxyquinomicin inhibits expression and production of inflammatory mediators in interleukin-1beta-induced human chondrocytes. Cell Physiol Biochem 2010 0.76
142 [A case of leptospirosis diagnosed early by flaB-PCR]. Kansenshogaku Zasshi 2003 0.76
143 pH-dependent inhibition of mushroom tyrosinase by N-substituted N-nitrosohydroxylamines. J Enzyme Inhib Med Chem 2008 0.76
144 p53 dysfunction precedes the activation of nuclear factor-κB during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. Carcinogenesis 2013 0.76
145 Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage. Transplantation 2013 0.76
146 Earthworm-derived pore-forming toxin lysenin and screening of its inhibitors. Toxins (Basel) 2013 0.76
147 Acute oral selenium intoxication with ten times the lethal dose resulting in deep gastric ulcer. J Emerg Med 2004 0.76
148 Interferon gamma induces steroid sulfatase expression in human keratinocytes. Biol Pharm Bull 2012 0.76
149 Novel approaches to target cancer initiating cells-eliminating the root of the cancer. Adv Biol Regul 2012 0.76
150 Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells. Oncol Res 2016 0.75
151 Determination of the absolute structure of (+)-akaterpin. Chem Pharm Bull (Tokyo) 2012 0.75
152 Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response. J Immunol 2013 0.75
153 Isolation of heptadepsin, a novel bacterial cyclic depsipeptide that inhibits lipopolysaccharide activity. Chem Biol 2004 0.75
154 DSE-FRET: A new anticancer drug screening assay for DNA binding proteins. Cancer Sci 2014 0.75
155 3-[(dodecylthiocarbonyl)methyl]-glutarimide attenuates graft arterial disease by suppressing alloimmune responses and vascular smooth muscle cell proliferation. Transplantation 2015 0.75
156 Down-regulation of TNF-alpha receptors by conophylline in human T-cell leukemia cells. Int J Oncol 2003 0.75
157 Synergistic anti-viral effect of oxanosine and ddI against human immunodeficiency virus. Biomed Pharmacother 2005 0.75
158 Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. Cancer Sci 2011 0.75
159 Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. Transplantation 2012 0.75
160 Target-selective degradation of cancer-related proteins by novel photosensitizers for molecular-targeted photodynamic therapy. Cancer Sci 2009 0.75
161 Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway. Biochem Biophys Res Commun 2013 0.75
162 Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB. Bioorg Med Chem Lett 2009 0.75
163 Unusual intramolecular N-->O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine. Bioorg Med Chem Lett 2009 0.75
164 The Implementation of a Hospital-wide Practice for the Selective Use of Carbapenems Based on the Monitoring of Susceptibility of Pseudomonas aeruginosa Isolates. Tokai J Exp Clin Med 2017 0.75
165 Diabetes mellitus: rational basis, clinical approach and future therapy. Biomed Pharmacother 2004 0.75
166 Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells. Oncol Res 2016 0.75
167 Activator protein-1 inhibition by 3-[(dodecylthiocarbonyl)methyl]-glutamaride impairs invasion and radiosensitizes osteosarcoma cells in vitro. Cancer Biother Radiopharm 2013 0.75
168 Inhibition of canonical NF-κB nuclear localization by (-)-DHMEQ via impairment of DNA binding. Oncol Res 2015 0.75
169 Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells. Int Arch Allergy Immunol 2015 0.75
170 Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ. Biochem Biophys Res Commun 2008 0.75
171 Molecular design, chemical synthesis, and biological evaluation of agents that selectively photo-degrade the transcription factor estrogen receptor-α. Org Biomol Chem 2011 0.75
172 Cytostatic in vitro effects of DTCM-glutarimide on bladder carcinoma cells. Asian Pac J Cancer Prev 2012 0.75
173 Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components. Bioorg Med Chem Lett 2011 0.75
174 Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions. Bioorg Med Chem 2002 0.75
175 Structure-activity relationship of 9-methylstreptimidone, a compound that induces apoptosis selectively in adult T-cell leukemia cells. Oncol Res 2012 0.75
176 A chemo-enzymatic expeditious route to racemic dihexanoyl (2R*,3R*,4R*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor for lipase-catalyzed synthesis of the potent nuclear factor-κB inhibitor, (2S,3S,4S)-DHMEQ. Chem Pharm Bull (Tokyo) 2012 0.75